| Date | Title | Description |
| 14.03.2024 | Cumulus Neuroscience Announces First Patient Enrolled in Acc... | NIHR-Funded Study Represents the Largest of its Kind Conducted to Date in Alzheimer's Dementia.
Cumu... |
| 12.03.2024 | Prilenia Plans to Submit Marketing Authorization Application... | -Following positive pre-submission meetings with regulators, Prilenia plans to submit its MAA for pr... |
| 11.03.2024 | Nitrase Therapeutics Unveils Pioneering Antibody Candidate f... | -Nitrase’s first-in-class antibody found to significantly delay progression of Parkinson’s disease i... |
| 11.03.2024 | Ribometrix to Present New Preclinical Data From RNA-Modulati... | — Data demonstrate in vivo tumor regression via RNA-binding protein inhibitor targeting eIF4E in mul... |
| 08.03.2024 | On International Women's Day SV Venture Partner Ruth McKerna... | On International Women’s Day it is extremely pleasing to note the vast majority of SV Health Investo... |
| 04.03.2024 | QurAlis to Present Data That Show its Splice-Switching ASOs ... | UNC13A is an essential regulator of neurotransmitter release at synapses; mis-splicing is a critical... |
| 13.02.2024 | BioAge raises $170M as obesity spotlight shifts to oral opti... | BioAge Labs has reeled in the biotech industry’s largest private financing round so far in 2024 as t... |
| 13.02.2024 | Sudo Biosciences Announces Second Close of Upsized Series B ... | CARMEL, IN - Sudo Biosciences (“Sudo”), a biopharmaceutical company committed to designing and devel... |
| 13.02.2024 | Transposon Announces Final Results from a Phase 2 Study of i... | SAN DIEGO, Feb. 12, 2024 /PRNewswire/ -- Transposon Therapeutics, a biotechnology company developing... |
| 13.02.2024 | EyeBio targets registrational trial after early success of W... | EyeBio’s tri-specific Wnt agonist antibody improved visual and anatomical measures in a Phase Ib/IIa... |
| 13.02.2024 | BioAge Announces $170 Million Oversubscribed Series D Financ... | February 13, 2024 08:00 AM Eastern Standard Time
RICHMOND, Calif.--(BUSINESS WIRE)--BioAge Labs (“Bi... |
| 13.02.2024 | EyeBio Announces Positive Visual, Anatomic and Safety Data f... | Twelve week data from the Ph1b/2a AMARONE trial reveals Restoret to be well-tolerated in patients wi... |
| 07.02.2024 | Kate Bingham Participates in The Times' Health Commission Re... | The government’s former chief scientific adviser [Sir Patrick Vallance] told The Times Health Commis... |
| 24.01.2024 | Amphista Therapeutics announces new data demonstrating in vi... | Cambridge, UK, January 24th, 2024 – Amphista Therapeutics (“the Company” or “Amphista”), a leader in... |
| 19.01.2024 | Prilenia Announces Clinical Data in Support of its Plans to ... | NAARDEN, Netherlands and WALTHAM, Mass., 19 January 2024 --- Prilenia Therapeutics B.V., a clinical ... |
| 11.01.2024 | SV investment has resulted in the approval of 24 novel thera... | SV approved therapeutics |
| 08.01.2024 | SV is hiring: Analyst / Associate - Biotech team | Position Title: Analyst / Associate - Biotech team |
| 08.01.2024 | SV is hiring: Executive Assistant | Position Title: Executive Assistant – Venture Capital/Growth Equity Firm |
| 04.01.2024 | Boehringer Ingelheim licenses multiple Dark Antigens® from E... | Oxford, UK – January 04, 2024. Enara Bio today announces that Boehringer Ingelheim has exercised its... |
| 04.01.2024 | Sitryx announces collaboration partner Lilly has commenced a... | Oxford, UK – 4 January 2024 – Sitryx Therapeutics (“the Company”), a biopharmaceutical company focus... |
| 04.01.2024 | SV Health Investors bolsters senior biotech team - appoints ... | LONDON - BOSTON, 04 January 2024 (GLOBE NEWSWIRE) - SV Health Investors, a leading transatlantic ven... |
| 03.01.2024 | QurAlis Strengthens Global Presence With Opening of European... | New location in Leiden, The Netherlands will serve as hub for European operations and production of ... |
| 20.12.2023 | Perfuze® Announces FDA Clearances for Novel Neurovascular As... | Galway, Ireland, December 20, 2023 –Perfuze, a private medical device company dedicated to developin... |
| 13.12.2023 | Hightop Health adds industry veteran to Board of Directors -... | Atlanta, GA (December 13, 2023) –Hightop Health, a premier outpatient mental health platform, today ... |
| 28.11.2023 | Harness Therapeutics secures additional £4 million funding t... | Cambridge, UK, 28th November 2023: Harness Therapeutics (‘Harness’, previously Transine Therapeutics... |
| 21.11.2023 | Merck to Acquire Caraway Therapeutics, Inc. | Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative di... |
| 21.11.2023 | Dementia Discovery Fund Announces the Acquisition of Caraway... | This transaction highlights DDF’s attractive strategy of investing in novel therapeutics for dementi... |
| 14.11.2023 | EyeBio Announces Expansion of Series A to $130 Million, Adva... | EyeBio doubles the size of its original Series A raise with an additional $65 million, with new inve... |
| 14.11.2023 | Transposon Announces Interim Results from a Phase 2 Study of... | 24-Week data show TPN-101 is the first treatment for PSP to reduce NfL levels, a key biomarker of ne... |
| 13.11.2023 | Cerevance Doses First Patient in ASCEND Phase 2 Clinical Stu... | Boston, MA – November 13, 2023 – Cerevance, a company focused on developing novel precision therapeu... |
| 12.11.2023 | Imbria Reports Positive Topline Results for Investigational ... | – The IMPROVE-ISCHEMIA Phase 2 clinical trial met the primary endpoint of tolerability and safety; 8... |
| 08.11.2023 | SV Health Investors partners with HIT Executives Dave Dyell ... | Panama City, Fla.—November 8, 2023—SV Health Investors (SVHI), a private healthcare investment firm ... |
| 07.11.2023 | Imbria Reports Positive Topline Results for Investigational ... | – The IMPROVE-HCM Phase 2 clinical trial met the primary endpoint of safety and tolerability; 12-wee... |
| 06.11.2023 | AviadoBio Announces FDA IND Clearance and Fast Track Designa... | • AVB-101 is an investigational gene therapy delivered as a one-time infusion directly to the brain,... |
| 02.11.2023 | Perfuze Announces First Stroke Patient Enrolled in the MARRS... | Galway, Ireland, November 2, 2023 –Perfuze, a private medical device company dedicated to developing... |
| 01.11.2023 | Vibrato Medical Announces Positive Results for Early Feasibi... | NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Vibrato Medical, an innovator in the treatment of peripheral... |
| 01.11.2023 | Sitryx announces partner Lilly exercises option to SIT-011 f... | Oxford, UK – 1 November 2023 – Sitryx Therapeutics (“the Company”), a biopharmaceutical company focu... |
| 23.10.2023 | Hightop Health Launches Unique Outpatient Mental Health Plat... | Boston, MA (October 23, 2023) – SV Health Investors (“SVHI”), a Boston-based healthcare private inve... |
| 18.10.2023 | Cumulus Neuroscience to Present Data at CTAD 2023 Annual Mee... | BELFAST, Northern Ireland and CAMBRIDGE, Mass., October 18, 2023 / -- Cumulus Neuroscience (Cumulus;... |
| 16.10.2023 | Pulmocide Announces New Clinical Data Confirming Low Potenti... | LONDON, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Pulmocide Ltd., (“the Company”) a late-stage biopharmaceut... |
| 12.10.2023 | Mestag Therapeutics announces the appointment of expert advi... | Cambridge, UK, October 12, 2023 – Mestag Therapeutics (“Mestag”), a biotech company harnessing new i... |
| 10.10.2023 | AviadoBio Announces Initiation of Phase 1/2 Clinical Trial, ... | • AVB-101 is an investigational gene therapy designed to halt disease progression by delivering a fu... |
| 09.10.2023 | AstronauTx closes a £48 million ($61 million) Series A finan... | London UK, XXXX– AstronauTx Ltd. (“AstronauTx”), a biotech company developing novel treatments for A... |
| 08.10.2023 | UK biotech group raises £48mn for Alzheimer’s research | AstronauTx’s financing is step towards helping millions of people suffering from disease |
| 05.10.2023 | Sean M. Healey & AMG Center for ALS awarded NIH U01 Gran... | The Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital has been awarded a gra... |
| 29.09.2023 | The Guardian: Pioneering a new era for dementia care | DDF Understanding Dementia |
| 27.09.2023 | Sitryx raises additional $39 million to progress development... | Oxford, UK – 27 September 2023 – Sitryx Therapeutics (“the Company”), a biopharmaceutical company fo... |
| 06.09.2023 | Nimbus Therapeutics Secures $210M Private Financing to Advan... | – GV joins the company’s distinguished investor base, validating Nimbus’ computational drug discover... |
| 06.09.2023 | Nimbus is back for more, raising $210M to fuel pipeline seve... | What kind of biotech company returns billions to its investors without ever opening a lab, commercia... |
| 03.09.2023 | British biotech faces a funding battle in race with the US | Quell Therapeutics, an SV portfolio company which recently entered into an exclusive option and lice... |
| 28.08.2023 | Fierce Biotech Names Cerevance a “Fierce 15” Biotech Company... | Boston, MA – August 28, 2023 – Cerevance, a private, clinical-stage drug discovery and development c... |
| 16.08.2023 | Imbria Pharmaceuticals Completes Enrollment in the Phase 2 I... | – IMPROVE-ISCHEMIA, a randomized, placebo-controlled trial, with topline data expected in 4Q 2023 –... |
| 07.08.2023 | Ikena Oncology Acquires Pionyr Immunotherapeutics in All-Sto... | Ikena receives approximately $43 million in net cash at closing |
| 25.07.2023 | A born listener: CNS startup Violet hones in on cellular cro... | The identification of new targets in diseases of the central nervous system (CNS) such as Alzheimer’... |
| 17.07.2023 | AI-Enabled Senior Care Company CarePredict Scores $29M | The company will use the funds to speed up its growth. |
| 06.07.2023 | DDF: Unleashing innovation, a new era for dementia | Dementia, the looming health crisis of our time, has long lacked effective treatments. But now, rece... |
| 28.06.2023 | Renowned Neuroscientist Prof. Michael Heneka, M.D, Joins The... | Boston, MA (US) and London (UK) –June 28th 2023. The Dementia Discovery Fund (DDF), the world’s larg... |
| 27.06.2023 | Mestag Therapeutics and VIB enter into an exclusive partners... | Cambridge, UK, and Ghent, Belgium, June 27, 2023 – Mestag Therapeutics (‘Mestag’), an immunotherapy ... |
| 26.06.2023 | SV Health Investors Completes Partnership with Packaging Com... | Boston, MA (June 26, 2023) – SV Health Investors (“SVHI”), a Boston-based private investment firm fo... |
| 20.06.2023 | SV Health Investors Acquires Robling Medical | Boston, MA(June 20, 2023) – SV Health Investors (“SVHI”), a Boston-based private investment firm foc... |
| 14.06.2023 | EyeBio Announces First Patients Dosed in Phase 1b/2 Trial of... | AMARONE (Anti-permeability Mechanism and Age-Related Ocular Neovascularization Evaluation) is first ... |
| 13.06.2023 | Autifony Therapeutics announces commencement of a US Phase I... | Stevenage, UK - 13 June 2023 - Autifony Therapeutics Limited (“Autifony”), which is pioneering the d... |
| 09.06.2023 | UK cell therapy start-up agrees AstraZeneca partnership wort... | Quell Therapeutics is developing cell engineering that aims to treat autoimmune diseases |
| 09.06.2023 | Quell Therapeutics Signs a Collaboration, Exclusive Option a... | London, UK – June 9 2023 – Quell Therapeutics Ltd (“Quell”), a leader in developing engineered T-reg... |
| 08.06.2023 | Pulmocide Announces Expansion of Management Team | LONDON, June 08, 2023 (GLOBE NEWSWIRE) -- Pulmocide Ltd., (“the Company”) a late-stage biopharmaceut... |
| 05.06.2023 | Imbria Pharmaceuticals Completes Enrollment in Phase 2 IMPRO... | – Enrollment exceeded expectations, thus highlighting the large unmet need in non-obstructive hypert... |
| 31.05.2023 | Violet Therapeutics raises $10.6 million in seed funding led... | Round led by the DDF (through DDF-2) and co-led by UTEC (University of Tokyo Edge Capital Partners) ... |
| 31.05.2023 | Cumulus Neuroscience Completes Patient Enrollment for Pivota... | Oxford and Cambridge Among Sites Participating in CNS-101 Validation Study |
| 19.05.2023 | First Steps to Treating Dementia May Lie in Related Diseases | AARP-backed research into ALS, Alzheimer’s could lead to dementia drugs |
| 15.05.2023 | Therini Bio Initiates First-In-Human Dosing in Phase 1 Trial... | SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Therini Bio, Inc., a biotech company focused on develo... |
| 01.05.2023 | Astellas Pharma buys Iveric Bio for $5.9 billion | Japan's Astellas Pharma said on Monday it agreed to buy U.S. drugmaker Iveric Bio Inc for about $5.9... |
| 27.04.2023 | Therini Bio Raises $36M Series A Financing to Develop Fibrin... | Funding from top-tier syndicate will be used to advance potential first-in-class investigational ant... |
| 18.04.2023 | Nitrase Therapeutics Presents Preclinical Data on the Role o... | BRISBANE, Calif., April 18, 2023 (GLOBE NEWSWIRE) -- Nitrase Therapeutics, Inc., a biopharmaceutical... |
| 06.04.2023 | QurAlis Announces First Patient Dosed With QRL-201, a First-... | First patient dosed in Canada in Phase 1 ANQUR study – the first-ever clinical trial to evaluate a t... |
| 28.03.2023 | Bicycle Therapeutics Announces a Strategic Collaboration wit... | - Bicycle and Novartis will collaborate on the discovery and development of multiple targeted radiol... |
| 28.03.2023 | Prilenia Achieves Last Patient Last Visit in Phase 3 PROOF-H... | PROOF-HD is the only late-stage study in Huntington’s disease targeting clinical progression; toplin... |
| 09.03.2023 | QurAlis Closes $88 Million Series B Financing to Advance Pre... | EQT Life Sciences, Droia Ventures, and Sanofi Ventures led the round |
| 09.03.2023 | ALS biotech QurAlis gets $88M boost from four pharmas for pa... | QurAlis picked up $88 million for two Phase I studies, hoping to ride regulatory waves driven by the... |
| 06.03.2023 | EyeBio Announces First Asset in Innovative Pipeline of Retin... | Additions to EyeBio’s leadership team include world-class disrupters with deep experience addressing... |
| 23.02.2023 | Prilenia Announces Topline Results for Pridopidine in Phase ... | Naarden, NL and WALTHAM, Mass, 23 February 2023 – Prilenia Therapeutics B.V., a clinical stage biote... |
| 23.02.2023 | AviadoBio Signs Exclusive License Agreement with Neurgain Te... | • Subpial delivery technology has the potential to offer precise, efficient, and safer delivery of g... |
| 20.02.2023 | Impact funds help fight dementia and antibiotic resistance | Some of the world’s biggest health challenges do not lend themselves to conventional investment |
| 16.02.2023 | Perfuze Announces FDA Clearance and First U.S. Clinical Use ... | GALWAY, Ireland--(BUSINESS WIRE)--Perfuze, a medical device company developing next-generation cathe... |
| 13.02.2023 | Cerevance Expands Series B Financing with Additional $51 Mil... | Proceeds will advance Cerevance’s potential first-in-class programs developed using proprietary NETS... |
| 08.02.2023 | Nimbus Therapeutics Announces Closing of Takeda's Acquisitio... | BOSTON, Mass. – February 8, 2023 – Nimbus Therapeutics, LLC (“Nimbus Therapeutics” or “Nimbus”), a c... |
| 25.01.2023 | HPS/PayMedix Closes on $25 Million in New Funding | Credit funds managed by SVB Capital lead new funding round to finance growth of PayMedix Healthcare ... |
| 24.01.2023 | Britain is losing its chance to become a life sciences super... | Short-termism and suspicion in parts of government risk our valuable future in precision medicine |
| 16.01.2023 | British Patient Capital and Mubadala Invest in SV Biotech Cr... | 16 January 2023: British Patient Capital and Mubadala Investment Company (Mubadala), an Abu Dhabi-ba... |
| 12.01.2023 | Feinstein Institutes, Northwell Use Ultrasound to Treat Brai... | Researchers enrolled the first set of patients in the Alpheus Medical phase 1 clinical trial for peo... |
| 09.01.2023 | Imbria Enrolls First Patient in the Phase 2 IMPROVE-DiCE Cli... | BOSTON, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Imbria Pharmaceuticals, Inc., a clinical stage, cardiometa... |
| 09.01.2023 | Exclusive: Eli Lilly boosts inflammatory disease pipeline, l... | Eli Lilly is adding three new preclinical candidates to its immune and inflammatory medicines armory... |
| 09.01.2023 | TRexBio Announces Collaboration and License Agreement with L... | Collaboration leverages TRexBio’s Deep Biology platform, which maps regulatory T cell (Treg) behavio... |
| 05.01.2023 | QurAlis Announces First-in-Human Dose in Phase 1 Clinical Tr... | QRL-101 aims to reduce hyperexcitability-induced motor neuron degeneration |
| 26.12.2022 | Why a lucky few may help the rest of us beat disease | A British biotech firm [Alchemab] believes patients who defy odds could hold the key in their blood,... |
| 20.12.2022 | Mestag Therapeutics appoints Prof. Ton Logtenberg as Chair | CAMBRIDGE, England, Dec. 20, 2022 /PRNewswire/ -- Mestag Therapeutics ("Mestag"), an immun... |
| 13.12.2022 | Dementia Discovery Fund invests in Amphista Therapeutics as ... | Cambridge, UK – December 13, 2022 – Amphista Therapeutics, a leader in next generation targeted prot... |
| 13.12.2022 | Takeda to Acquire Nimbus Therapeutics’ Highly Selective, All... | – Nimbus to receive $4 billion in upfront cash, and up to $2 billion in commercial milestone payment... |
| 13.12.2022 | In its largest single-asset purchase ever, Takeda snaps up T... | Takeda is buying Nimbus’ late-stage TYK2 inhibitor, an oral drug for autoimmune diseases, for $4 bil... |
| 08.12.2022 | QurAlis Receives Health Canada Clinical Trial Application Au... | First ever study to evaluate a therapy that rescues STATHMIN-2 expression in ALS patients expected t... |
| 06.12.2022 | Alison Burkland, co-founder of MCF portfolio company Nanopat... | Alison Burklund is the cofounder and CTO of Nanopath. Nanopath creates diagnostics that test pelvic ... |
